GO
Loading...

Merck & Co Inc

More

  • Esperion jumps on high-cholesterol drug data Wednesday, 1 Oct 2014 | 5:46 PM ET

    NEW YORK— Shares of Esperion Therapeutics surged in aftermarket trading Wednesday after the company reported positive clinical trial results for its experimental high-cholesterol drug ETC-1002. The company said patients who were treated with ETC-1002 had bigger reductions in their levels of "bad" LDL cholesterol than patients who took an older drug,...

  • Oct 1- An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer...

  • Oct 1- A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • NEW YORK, Sept 29- U.S. stock index futures were lower on Monday, indicating Wall Street's recent weakness would continue amid ongoing civil unrest in Hong Kong.

  • MADRID, Sept 28- Merck& Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • *AstraZeneca says tolerability profile encouraging. MADRID, Sept 27- Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system suggest the cocktail is promising, though limited patient numbers mean the data is far from conclusive.

  • Your first trade for Tuesday Monday, 22 Sep 2014 | 6:01 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Early movers: SIAL, MSFT, BABA, GOOG, GM & more Monday, 22 Sep 2014 | 7:37 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • German Merck to buy St. Louis-based Sigma-Aldrich Monday, 22 Sep 2014 | 6:49 AM ET

    FRANKFURT, Germany— German drug company Merck says it has agreed to buy St. Louis- based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment.

  • PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.

  • *Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.

  • Sept 15- Merck& Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • Why Thomas Lee is bullish on stocks Monday, 15 Sep 2014 | 11:04 AM ET
    Thomas Lee, JPMorgan's U.S. equity strategist

    Stock market strategist Thomas Lee says there's plenty of proof the bull market still has several years to go.

  • Stocks close down ahead of Fed meeting; energy hit Friday, 12 Sep 2014 | 4:07 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed down on Friday, breaking five weeks of consecutive gains as investors awaited the Federal Reserve's announcement next Wednesday.

  • JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.

  • Vamil Divan, Senior Analyst, U.S. Pharmaceuticals at Credit Suisse, discusses news that Bristol-Myers Squibb and Ono Pharmaceutical are suing Merck over the Keytruda cancer drug.

  • Can anything slow Gilead down? Analysts say no Monday, 8 Sep 2014 | 3:12 PM ET
    Darryl Kato, research scientist for Gilead Sciences, works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster City, California, Feb. 8, 2012.

    Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.